Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma - Summary - MDSpire

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

  • By

  • Iskander Musabaev

  • Sergey Goryaynov

  • Tatiana Yu Kochetova

  • Valerii Krylov

  • Sergey Ivanov

  • May 29, 2026

  • 0 min

Share

Objective:

To evaluate the effects of [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma.

Key Findings:
  • 99.8% decrease in PSA levels post-treatment.
  • 90.6% reduction in meningioma size.
  • Stable hematological parameters throughout the observation period.
  • High-grade xerostomia was noted as an adverse effect.
Interpretation:

Remove unsupported claims about effectiveness.

Limitations:
  • The study is based on a single patient case report.
  • Lack of phase III clinical trial data for [225Ac]Ac-PSMA-617.
Conclusion:

Revise to avoid unsupported claims about the potential of the therapy.

Original Source(s)

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

  • by Iskander Musabaev, Sergey Goryaynov, Tatiana Yu Kochetova, Valerii Krylov, Sergey Ivanov

  • May 29, 2026

Related Content

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report